Gemtuzumab Ozogamicin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Gemtuzumab ozogamicin: From Acute Myeloid Leukemia to Richter Syndrome
One-Sentence Summary
Gemtuzumab ozogamicin is a CD33-targeted antibody-drug conjugate, originally used to treat acute myeloid leukemia (AML). The TxGNN model predicts it may be effective for Richter syndrome, but no clinical trials and no publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute myeloid leukemia (the Singapore license record has no indication text, so this comes from the drug's knowledge-graph indications) |
| Predicted New Indication | Richter syndrome |
| TxGNN Prediction Score | 98.06% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known information, gemtuzumab ozogamicin delivers a cytotoxic calicheamicin payload to cells that express CD33. Its efficacy in AML is established, so a mechanistic link to other CD33-expressing blood cancers is plausible.
For Richter syndrome, that link is weak. Richter syndrome is typically a large B-cell transformation of chronic lymphocytic leukemia that is CD20-positive and CD33-negative. This means the drug's target is probably absent on the cancer cells. The high TxGNN score (98.06%) is a model output only. It is not backed by any trial or publication, so it should be treated as a hypothesis rather than a finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN16243P | MYLOTARG Powder for Concentrate for Solution for Infusion 5 mg/vial | Powder, for solution |
This is one valid single-ingredient license, held by Wyeth Pharmaceutical Division of Wyeth Holdings LLC. The record contains no approved-indication text.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate carrying a cytotoxic calicheamicin payload (targeted cytotoxic therapy) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count and liver function (hepatic toxicity is a recognized concern with this drug) |
| Handling Protection | Follow institutional cytotoxic drug handling procedures |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interactions in total. The 20 shown in the data compiled for this report include four rated Major:
- Deferiprone
- Samarium (153Sm) lexidronam
- Adalimumab
- Baricitinib
Most of the other interactions shown are rated Moderate (for example naltrexone, alemtuzumab, azathioprine, zidovudine, chloramphenicol). Levofloxacin is rated Minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials or literature. The drug's target (CD33) is probably absent in Richter syndrome, so the mechanistic basis is weak.
To proceed, the following is needed:
- Evidence that Richter syndrome cells express CD33, for example from immunophenotyping data
- Any preclinical or clinical data of the drug in Richter syndrome or related B-cell transformations
- The Singapore package insert warnings and contraindications (including hepatic safety)
- Detailed mechanism-of-action data
- Review of other predicted indications that have better supporting evidence, such as blast-phase chronic myeloid leukemia, where preclinical and case-report data exist
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.